A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

3Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

Objective: Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH). We evaluated the potential benefit of combining both strategies. Design: Forty-two PLWH aged ≥40 years receiving a protease inhibitor (PI)-based regimen were randomized (1:1) to switch from PI to Raltegravir (n = 20), or to remain on PI (n = 22). After 24 weeks, all patients received atorvastatin 20mg/day for 48 weeks. Methods: We analyzed plasma inflammatory as well as T-cell maturation, activation, exhaustion and senescence markers at baseline, 24 and 72 weeks, Results: Plasma inflammatory markers remained unchanged. Furthermore, no major changes on T-cell maturation subsets, immunoactivation, exhaustion or immunosenescence markers in both CD4 and CD8 T cell compartments were observed. Only a modest decrease in the frequency of CD38+ CD8 T cells and an increase in the frequency of CD28-CD57+ in both CD4 and CD8 T-cell compartments were noticed in the Raltegravir-switched group. Conclusions: The study combined antiretroviral switch to Raltegravir and Statin-based anti-inflammatory strategies to reduce inflammation and chronic immune activation in PLWH. Although this combination was safe and well tolerated, it had minimal impact on inflammatory and immunological markers.

References Powered by Scopus

Aging with multimorbidity: A systematic review of the literature

2057Citations
N/AReaders
Get full text

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

1366Citations
N/AReaders
Get full text

Plasma levels of soluble CD14 independently predict mortality in HIV infection

932Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Lack of atorvastatin effect on monocyte gene expression and inflammatory markers in hiv-1-infected art-suppressed individuals at risk of non-aids comorbidities

4Citations
N/AReaders
Get full text

Pharmacological and Behavioral Interventions to Mitigate Premature Aging in Patients with HIV

1Citations
N/AReaders
Get full text

Synthesis of dolutegravir derivatives modified by 1,2,3-triazole structure and their anti-inflammatory activity in LPS-induced BV2 cells

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Negredo, E., Jiménez, M., Puig, J., Loste, C., Pérez-Álvarez, N., Urrea, V., … Blanco, J. (2020). A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE, 15(9 September). https://doi.org/10.1371/journal.pone.0238575

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

55%

Researcher 3

27%

Lecturer / Post doc 2

18%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

43%

Nursing and Health Professions 7

33%

Immunology and Microbiology 3

14%

Pharmacology, Toxicology and Pharmaceut... 2

10%

Save time finding and organizing research with Mendeley

Sign up for free